FindTrial
Sign In

The influence of albumin/prealbumin on anastomotic leakage in esophageal cancer patient treated with neoadjuvant chemotherapy combined with immunotherapy followed by minimally invasive esophagectomy

The influence of albumin/prealbumin on anastomotic leakage in esophageal cancer patient treated with neoadjuvant chemotherapy combined with immunotherapy followed by minimally invasive esophagectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066694
Enrollment
Unknown
Registered
2022-12-14
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

neoadjuvant group:neoadjuvant chemotherapy combined with immunotherapy
surgical group:N/A

Sponsors

Department of thoracic surgery, Army medical center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.squamous cell carcinoma of esophagus 2.non history of thoracic surgery 3.minimally invasive esophagectomy

Exclusion criteria

Exclusion criteria: 1.80 year old 2.R1 or R2 resection 3.severe comorbidity

Design outcomes

Primary

MeasureTime frame
albumin level;prealbumin level;incidence of anastomotic leakage;—

Countries

China

Contacts

Public ContactWei Guo

Department of thoracic surgery, Army medical center

gyguowei@hotmail.com13527323568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026